Find Clinical Trials

Back My cancer has not gone away or has come back Cancer progressed on treatment

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

I want to enter information about my genetic testing (e.g, BRCA) and/or tumor testing results

I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

III

Platinum resistant ovarian cancer

Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

CA, FL, IN, LA, OH, OK, PA, WV

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
Docetaxel	Taxotere	Microtubule stabilizer/mitotic inhibitor	Approved in Other Cancers
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Topotecan	Hycamptamine, Hycamtin, TOPO	Topoisomerase I inhibitor	Approved in Ovarian Cancer

III

Platinum resistant high grade serous or high grade endometrioid ovarian cancer that must have had prior bevacizumab

A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)

AZ, CA, CO, GA, IL, KS, KY, NM, OH, OR, SD, TX, VA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
nab-Paclitaxel	Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007	Microtubule stabilizer/mitotic inhibitor	NCCN Guidelines for Ovarian Cancer
Relacorilant	RELA, CORT125134	GR antagonist	Clinical Trials

III

Platinum resistant or refractory ovarian cancer that must have had prior bevacizumab

A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Platinum-doublet Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)

CA, FL

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
Olvimulogene nanivacirepvec	light-emitting oncolytic vaccinia virus GL-ONC1, GLV-1h68, GL-ONC1	Induces immune response and tumor cell lysis	Clinical Trials

III

Platinum resistant or refractory high grade serous or endometrioid ovarian cancer without germ-line BRCA1/2 mutations

EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer

AZ, AR, CA, FL, IL, MD, MA, NY, OH, SD, TN, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Alpelisib	PI3K inhibitor BYL719, BYL719, phosphoinositide 3-Kinase inhibitor BYL719, Piqray	PI3K alpha inhibitor	Approved in Other Cancers
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer

III

Platinum resistant or refractory ovarian cancer that must have had prior bevacizumab (5 or less prior therapies for platinum resistant disease)

A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)

AK, AZ, CA, FL, MD, MI, NJ, NM, NY, NC, OH, OR, SC, SD, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nemvaleukin alfa	intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230	IL-2R/IL-15R beta and gamma agonist	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

III

Platinum resistant ovarian cancer; 1-2 prior systemic therapies

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)

AZ, CA, CT, FL, GA, IL, IN, KY, LA, MD, MA, NJ, NY, NC, OH, OR, PA, SD, TN, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

IIb

Platinum resistant ovarian cancer; all lesions must be less than 4 cm

Phase 2b Single Arm Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects With Platinum-Resistant, Epithelial Ovarian Cancer.

CA, FL, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Maveropepimut-S	survivin antigen vaccine DPX-Survivac, DPX-Survivac	Immune response against cancer expressing survivin	Clinical Trials

II

Platinum resistant, refractory or persistent ovarian cancer (no measurable disease outside the peritoneal cavity)

MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer

AZ, FL, MN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
MV-NIS	oncolytic measles virus encoding thyroidal sodium iodide symporter	Induces immune response and tumor cell lysis	Clinical Trials

II

Advanced solid tumors (with tumor amenable to skin biopsy)

DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Capecitabine	Xeloda, CAPE	RNA processing and thymidylate synthase inhibitor	NCCN Guidelines for Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
nab-Paclitaxel	Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007	Microtubule stabilizer/mitotic inhibitor	NCCN Guidelines for Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with moderate/high TMB

Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

KY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Tremelimumab	Ticilimumab, CP-675206, CP-675,206, CP-675, anti-CTLA4 human monoclonal antibody CP-675,206	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with IDH1 mutations

Phase II Study of IDH1 Inhibitor Ivosidenib and Nivolumab in IDH1 Mutant Gliomas and Advanced Solid Tumors

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ivosidenib	AG-120	IDH1 inhibitor	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors

A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin		IL-2R agonist	Approved in Other Cancers
Autologous TILs		Immune response against tumor-associated antigens	Clinical Trials
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers

II

Granulosa cell ovarian cancer

A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Methoxyamine	TRC102	Base excision repair inhibitor	Clinical Trials
Temozolomide	Temodal, Temodar, Methazolastone	DNA damaging agent	Approved in Other Cancers

II

Advanced solid tumors - intratumoral injection

A Phase 2 Trial of Non-ablative Cryosurgical Freezing and Multiplex Immunotherapy in Patients With Metastatic Solid Cancer

AZ

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Thermotherapy			Clinical Trials

II

Recurrent ovarian cancer

Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers

AZ, FL, MN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Topotecan	Hycamptamine, Hycamtin, TOPO	Topoisomerase I inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with dMMR, high TMB or high MSI with limited progression on checkpoint inhibitor treatment

A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade

CT, NJ, NY, PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Radiation Therapy	Irradiation, Radiotherapy

II

Advanced solid tumors with c-Kit or PDGFRA mutations (except c-KIT V654A or T670I)

Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Avapritinib		PDGFRa and c-Kit inhibitor	Approved in Other Cancers

II

Advanced solid tumors with FGFR alterations

A Phase II Study of Oral Infigratinib in Adult Patients With Advanced or Metastatic Solid Tumors With FGFR1-3 Gene Fusions or Other FGFR Genetic Alterations

OH

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Infigratinib	BGJ398, pan FGFR Kinase Inhibitor BGJ398	pan-FGFR kinase inhibitor	Approved in Other Cancers

II

Recurrent Germ Cell Tumors

A Phase II Trial Evaluating the Efficacy of Cabozantinib in the Treatment of Incurable Patients With Refractory Germ Cell Tumors

IN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cabozantinib	BMS-907351, Cabometyx, XL184, Cometriq	Multi-targeted RTK inhibitor	Approved in Other Cancers

II

Recurrent high grade ovarian cancer or carcinosarcoma

Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin		IL-2R agonist	Approved in Other Cancers
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
LN-145-S1	Autologous Tumor Infiltrating Lymphocytes LN-145-S1, PD-1 selected TIL therapy	Immune response against tumor-associated antigens	Clinical Trials
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Recurrent ovarian cancer with symptomatic ascites or pleural effusion

Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion

NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Pegcetacoplan	C3-targeted complement inhibitor APL-2, APL-2	Blocks the cleavage of C3	Approved in Other Indications
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with ARID1A mutations

A Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Solid Tumors

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Platinum resistant or refractory clear cell ovarian cancer or mixed epithelial carcinoma with a clear cell component

Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Tremelimumab	Ticilimumab, CP-675206, CP-675,206, CP-675, anti-CTLA4 human monoclonal antibody CP-675,206	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with ATM mutations

A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)

CA, FL, LA, MD, MI, MN, NV, NY, PA, SC

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ceralasertib	ATR kinase inhibitor AZD6738, AZD6738	ATR kinase inhibitor	Clinical Trials

II

Recurrent ER+ and/or PR+ ovarian cancer with alterations in PIK3CA, PIK3R1 or PTEN

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Copanlisib	BAY 80-6946, PI3K inhibitor BAY 80-6946	pan-PI3K inhibitor	Approved in Other Cancers
Fulvestrant	ZD9238, ICI 182,780, Faslodex	ER antagonist (SERD)	Approved in Other Cancers

II

Advanced solid tumors with alterations in BRAF, RAF1, MEK1/2, ERK1/2 or NF1

A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.

IN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Temuterkib	LY3214996	ERK inhibitor	Clinical Trials

II

Advanced solid tumors with high MSI or high TMB

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)

CA, MA, NJ

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with leptomeningeal metastases

Phase II Trial of Pembrolizumab and Lenvatinib for Leptomeningeal Metastases

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Lenvatinib	MK-7902, Lenvima, ER-203492-00, E7080	Multi-targeted RTK inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Recurrect low grade serous ovarian cancer

Efficacy of Oral Regorafenib Combined With Intra-muscular Injection of Fulvestrant in Patients With Recurrent Low-grade Serous Ovarian Cancer: A Phase II Single Arm Trial

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Fulvestrant	ZD9238, ICI 182,780, Faslodex	ER antagonist (SERD)	Approved in Other Cancers
Regorafanib	BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga	Multi-targeted RTK inhibitor	Approved in Other Cancers

II

Platinum resistant or refractory high grade serous ovarian cancer with disease present in the peritoneal cavity or retroperitoneal lymph nodes

Immunomodulation of the Tumor Microenvironment in High-Grade Serous Ovarian Cancer Patients Receiving Pembrolizumab and Lenvatinib Monotherapy and Combination Therapy

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Lenvatinib	MK-7902, Lenvima, ER-203492-00, E7080	Multi-targeted RTK inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with brain metastases and NTRK, ROS1, CDK pathway or PI3K pathway alterations

Genomically-Guided Treatment Trial in Brain Metastases

AK, AZ, AR, CA, CO, CT, FL, GA, ID, IL, IA, KS, KY, LA, MA, MI, MN, MS, MO, MT, NE, NH, NJ, NY, NC, OH, OK, OR, PA, TX, UT, VT, WA, WI, WY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancers
Paxalisib	GDC-0084, PI3K inhibitor GDC-0084, RG7666	PI3K/mTOR inhibitor	Clinical Trials

II

Patients with progressive brain metastases with amplifications in CDK4, CDK6, CCND1, CCND2, CCND3 or CCNE1 or loss of CDKN2A

A Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK Pathway

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Palbociclib	PD-0332991, PD0332991, Ibrance	CDK4/6 inhibitor	Approved in Other Cancers

II

Advanced solid tumors

A Phase 2 Study of VLS-101 in Patients With Solid Tumors

FL, MA, NJ, NY, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Zilovertamab vedotin	MK-2140, VLS-101	ADC: anti-ROR1 + microtubule destabilizer (MMAE)	Clinical Trials

II

Advanced solid tumors with somatic mutations in ATM, BARD1, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCI/L, PALB2, PPP2R2A, RAD51B/C/D or RAD54L

A Phase II Trial of Niraparib and Dostarlimab Combination Therapy in Patients With Somatic Homologous Recombination Deficient Advanced or Metastatic Cancer

TN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Dostarlimab	TSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Niraparib	Zejula, MK4827	PARP inhibitor	Approved in Ovarian Cancer

II

Recurrent rare tumors

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nilotinib	AMN 107, Tasigna	Bcr-abl, c-Kit, and PDGFR kinase inhibitor	Approved in Other Cancers
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Recurrent or persistent non-mucinous ovarian cancer with peritoneal disease (IP/IV)

Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Ovarian, or Other Gynecologic Primary Cancer

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nilotinib	AMN 107, Tasigna	Bcr-abl, c-Kit, and PDGFR kinase inhibitor	Approved in Other Cancers
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with loss of function PTCH1 mutations

A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

CA, FL, IL, LA, NV, NY, NC, OH, PA, TN, TX, VA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Taladegib	LY2940680, ENV-101	Smoothened antagonist	Clinical Trials

II

Ovarian cancer with brain metastasis and alterations in ATM, ATR, BAP1, BARD1, BRCA1/2, BRIP1, MRE11A, NBN, PALB2, RAD50, RAD51B/C/D, RAD54B/L, XRCC2, or XRCC3 (with measurable disease in the CNS)

Genomically Guided Phase II Study to Evaluate the Clinical Benefit of Niraparib in Tumors Metastatic to the CNS

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Niraparib	Zejula, MK4827	PARP inhibitor	Approved in Ovarian Cancer

II

Recurrent serous, endometrioid or clear cell ovarian cancer

Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer

NY, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
CDX-1140		Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Recurrent ovarian cancer

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)

OR

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Alectinib	AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802	ALK kinase inhibitor	Approved in Other Cancers
Alpelisib	PI3K inhibitor BYL719, BYL719, phosphoinositide 3-Kinase inhibitor BYL719, Piqray	PI3K alpha inhibitor	Approved in Other Cancers
Anastrozole	Arimidex	Aromatase inhibitor
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Capecitabine	Xeloda, CAPE	RNA processing and thymidylate synthase inhibitor	NCCN Guidelines for Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Cobimetinib	XL518, GDC-0973, Cotellic	MEK1 inhibitor	Approved in Other Cancers
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancers
Eribulin	B1939 mesylate, E7389, ER-086526, Halaven, halichrondrin B analog	Microtubule destabilizer/mitotic inhibitor	Approved in Other Cancers
Fulvestrant	ZD9238, ICI 182,780, Faslodex	ER antagonist (SERD)	Approved in Other Cancers
Irinotecan	Campothecin-11, Campto, Camptosar	Topoisomerase I inhibitor	NCCN Guidelines for Ovarian Cancer
Letrozole	Femara	Aromatase inhibitor	NCCN Guidelines for Ovarian Cancer
nab-Paclitaxel	Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007	Microtubule stabilizer/mitotic inhibitor	NCCN Guidelines for Ovarian Cancer
Niraparib	Zejula, MK4827	PARP inhibitor	Approved in Ovarian Cancer
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Palbociclib	PD-0332991, PD0332991, Ibrance	CDK4/6 inhibitor	Approved in Other Cancers
Pertuzumab	Perjeta, monoclonal antibody 2C4, rhuMAb2C4	HER2 dimerization inhibitor	Approved in Other Cancers
Trastuzumab	Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody	HER2 antagonist	Approved in Other Cancers
Trastuzumab emtansine	trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine	ADC: anti-HER2 + microtubule destabilizer (DM1)	Approved in Other Cancers
Vemurafenib	RO5185426, PLX4032, Zelboraf	BRAF kinase inhibitor	Approved in Other Cancers
Vinorelbine	Biovelbin, Eunades, Navelbine, Navelbine ditartrate, NVB, Vinorelbine tartrate, VNB, Vinorelbine ditartrate	Microtubule destabilizer/mitotic inhibitor
Vismodegib	Hedgehog antagonist GDC-0449, Erivedge, GDC-0449	Smoothened antagonist	Approved in Other Cancers

II

Advanced HRD+ or LOH high solid tumors

A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer

AZ, CA, CO, GA, TX, UT, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with dMMR that must have had prior immunotherapy

Phase II Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy

NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Sirolimus	Rapamycin, Rapamune	mTOR inhibitor	Approved in Other Indications

II

Advanced solid tumors with IDH1 or IDH2 mutations

A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

CA, CT, FL, KS, MD, MA, MO, NH, NJ, NY, NC, OH, OK, PA, TN, TX, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors that must have progressed on prior immunotherapy or cellular therapy (amenable to radiation therapy)

Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Radiation Therapy	Irradiation, Radiotherapy

II

Platinum resistant ovarian cancer

A Phase II Trial of Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer

IL

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Minoxidil		Kir6/SUR2 channel activator	Approved in Other Indications

II

Advanced solid tumors

A PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINATION WITH PF-07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

MA, MI, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
PF-07104091		CDK2 inhibitor	Clinical Trials
PF-07220060		CDK4 inhibitor	Clinical Trials

II

Recurrent or persistent clear cell ovarian cancer

A Phase II Trial of Pembrolizumab and Lenvatinib in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Lenvatinib	MK-7902, Lenvima, ER-203492-00, E7080	Multi-targeted RTK inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with loss of SMARCB1 or SMARCA1

A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

AL, CA, DC, IN, MA, MI, MN, MO, NY, NC, OH, PA, TN, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Tiragolumab	MTIG7192A, RO7092284	Blocks TIGIT binding to PVR (CD155) and PVRL2 (CD112) to enable DNAM-1 (CD226) mediated activation of NK and CD8 T cells	Clinical Trials

II

Advanced solid tumors

A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin		IL-2R agonist	Approved in Other Cancers
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers
Individual Patient TCR-Transduced PBL	autologous PBLs retrovirally-transduced with TCRs targeting neoantigens	Immune response against neoantigens	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors

A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin		IL-2R agonist	Approved in Other Cancers
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Selected Young TIL		Immune response against tumor-associated antigens	Clinical Trials

II

Platinum sensitive ovarian cancer with first or second recurrence in peritoneal cavity

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Rintatolimod	Atvogen	TLR3 agonist and immune cell stimulator	Approved in Other Indications

II

Platinum sensitive high grade serous ovarian cancer with CA125-associated recurrence

Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer

NC, OK, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Niraparib	Zejula, MK4827	PARP inhibitor	Approved in Ovarian Cancer
Oregovomab	OvaRex, Monoclonal Antibody B43.13, B43.13	Immune response against cancer expressing CA125	Clinical Trials

II

Advanced solid tumors

A Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin		IL-2R agonist	Approved in Other Cancers
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers
Sleeping Beauty Transposed PBL		Immune response against neoantigens	Clinical Trials

II

Platinum resistant low-grade serous, low-grade endometrioid, clear cell, mucinous, undifferentiated, malignant Brenner tumors, small cell carcinoma of the ovary-hypercalcemic type or carcinosarcoma

A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

AZ, CA, MN, MO, NC, OH, OK, OR, PA, TX, UT, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Cobimetinib	XL518, GDC-0973, Cotellic	MEK1 inhibitor	Approved in Other Cancers
Giredestrant	GDC-9545, selective estrogen receptor downregulator GDC-9545	ER antagonist (SERD)	Clinical Trials
Inavolisib	RG6114, GDC-0077	PI3K alpha inhibitor	Clinical Trials
Ipatasertib	GDC-0068, Akt Inhibitor GDC-0068, RG7440	pan-AKT inhibitor	Clinical Trials
Letrozole	Femara	Aromatase inhibitor	NCCN Guidelines for Ovarian Cancer
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Palbociclib	PD-0332991, PD0332991, Ibrance	CDK4/6 inhibitor	Approved in Other Cancers
Trastuzumab emtansine	trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine	ADC: anti-HER2 + microtubule destabilizer (DM1)	Approved in Other Cancers

II

Recurrent ovarian cancer

Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3

MI, TX, UT, VA

Drug(s) in Trial	Other Drug Names